Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The British Society for Haematology (BSH) has been uniting hematology professionals since 1960. With 1,700+ members the society continues to transform patient care. We've been in Glasgow for the 2019 BSH Annual Scientific Meeting that's brought experts together to share research findings on topics such as CLL, AML, ALL, myeloma, lymphoma, and hemoglobinopathies. By interviewing experts, we've created an online archive, containing everything from the CAR-T revolution to care priorities in sickle cell disease.

BSH 2019

01–03 April 2019 | SEC Centre, Exhibition Way, Glasgow, UK

BSH 2019

01–03 April 2019 | SEC Centre, Exhibition Way, Glasgow, UK

The British Society for Haematology (BSH) has been uniting hematology professionals since 1960. With 1,700+ members the society continues to transform patient care. We've been in Glasgow for the 2019 BSH Annual Scientific Meeting that's brought experts together to share research findings on topics such as CLL, AML, ALL, myeloma, lymphoma, and hemoglobinopathies. By interviewing experts, we've created an online archive, containing everything from the CAR-T revolution to care priorities in sickle cell disease.

Inhibition of C3 with APL-2 in autoimmune hemolytic anemia to reduce hemolysis 1:53
Inhibition of C3 with APL-2 in autoimmune hemolytic anemia to reduce hemolysis
Bruno Fattizzo • 2 Apr 2019
Importance of asepsis research in hematology 1:35
Importance of asepsis research in hematology
Simon Clare • 2 Apr 2019
Communication between CLL patients and doctors 4:03
Communication between CLL patients and doctors
Ben Kennedy • 1 Apr 2019
Improved MRD response rates in CLL with obinutuzumab after ibrutinib exposure 1:38
Improved MRD response rates in CLL with obinutuzumab after ibrutinib exposure
Talha Munir • 1 Apr 2019
Infectious complications of CLL: prevention and treatment 5:41
Infectious complications of CLL: prevention and treatment
Ben Kennedy • 1 Apr 2019
Lessons learned from the CLL CLARITY study and ongoing follow-up 1:44
Lessons learned from the CLL CLARITY study and ongoing follow-up
Talha Munir • 1 Apr 2019
Allo-SCT upfront for MCL: feasible for a small subgroup? 3:05
Allo-SCT upfront for MCL: feasible for a small subgroup?
Simon Rule • 1 Apr 2019
MRD in pediatric ALL: clinical evidence, treatment decisions & outcomes 2:04
MRD in pediatric ALL: clinical evidence, treatment decisions & outcomes
Vaskar Saha • 1 Apr 2019
Advice for HCPs wanting to get into hematology clinical trials 2:18
Advice for HCPs wanting to get into hematology clinical trials
Simon Rule • 1 Apr 2019
Follow-up of the ALLR3 trial: pediatric late bone marrow relapse & lessons learned 3:08
Follow-up of the ALLR3 trial: pediatric late bone marrow relapse & lessons learned
Vaskar Saha • 1 Apr 2019
Defining the group of MCL patients who do well without treatment 2:15
Defining the group of MCL patients who do well without treatment
Simon Rule • 1 Apr 2019
International PNH Registry: studies, activity & eculizumab efficacy 2:30
International PNH Registry: studies, activity & eculizumab efficacy
Talha Munir • 1 Apr 2019
How increasing bureaucracy is affecting clinical research: self-defeating? 3:22
How increasing bureaucracy is affecting clinical research: self-defeating?
Simon Rule • 1 Apr 2019
Transitional care priorities for teenagers/young adults with SCD and chronic diseases 3:42
Transitional care priorities for teenagers/young adults with SCD and chronic diseases
Subarna Chakravorty • 2 Apr 2019
Enhancer landscape in CLL upon BTK inhibition 2:36
Enhancer landscape in CLL upon BTK inhibition
Efterpi Kostareli • 2 Apr 2019
BSH research grants 1:28
BSH research grants
Guy Pratt • 1 Apr 2019

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals